Saleemah Fahmi, MD
Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1922283506
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $908,613 of the $1,166,734 with a category attached, or 77.9%. 50 manufacturers reported payments, led by Lilly USA, LLC at 43.4% of the total. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,793 payments — averaging $417.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$506K
- Corcept Therapeutics$238K
- Amgen$173K
- Abbott$59K
- Shire North American Group Inc$46K
- AbbVie$31K
- plus $115K from 44 others
What the payments were for
- Consulting fees$60,4055%
- Speaking & faculty fees$908,61378%
- Travel & lodging$153,28113%
- Food & beverage$44,2824%
- Education$930%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$249,073
- Korlym$232,537
- MOUNJARO$156,269
- TEPEZZA$146,072
- JARDIANCE$71,440
- FREESTYLE LIBRE 3$53,943
- NATPARA (PARATHYROID HORMONE)$45,251
- Synthroid$27,468
- RECORLEV$23,392
- CYCLOSET$23,170
- SOLIQUA 100/33$20,223
- TOUJEO$7,167
- AFREZZA$4,513
- INVOKANA$2,715
- FreeStyle Libre$2,689
- DISEASE STATE$2,530
- Macrilen$773
- MINIMED 780G$563
- FARXIGA$195
- Minimed 630G$191
How this compares
$1,166,734 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 45 | $1,498,945 |
| OzempicSemaglutide | 478 | $611,825 |
| MounjaroTirzepatide | 459 | $572,740 |
| JardianceEmpagliflozin | 352 | $343,702 |
| TrulicityDulaglutide | 246 | $337,981 |
| Tresiba Flextouch U-200Insulin Degludec | 232 | $241,067 |
| FarxigaDapagliflozin Propanediol | 232 | $204,486 |
| AfrezzaInsulin Regular, Human | 46 | $96,041 |
| ProliaDenosumab | 46 | $80,707 |
| Humalog Kwikpen U-200Insulin Lispro | 19 | $70,402 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $70,195 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 53 | $64,498 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 58 | $54,879 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 36 | $35,208 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $33,437 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $237,604 | $1,498,94545 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $505,930 | $932,083790 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $5,344 | $662,396549 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $17,515 | $413,731432 claims |
| AstraZenecaFarxiga | $1,351 | $204,486232 claims |
| Mannkind CorporationAfrezza | $6,244 | $96,04146 claims |
| AmgenProlia | $172,669 | $80,70746 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCCycloset | $24,394 | $30,96728 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $25,496 | $29,47018 claims |
| MerckJanuvia | $306 | $27,90749 claims |
| AbbVieSynthroid | $30,726 | $19,847243 claims |
| Cequr CorporationCequr Simplicity | $56 | $12,54211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Dallas
- Pablo MoraDallas$1.3M
- Steve FordanDallas$1.2M
- Julio RosenstockDallas$1.2M
- Ildiko LingvayDallas$711K
- Rajiv DattatreyaDallas$437K
- Jaime AlmandozDallas$334K
- Luigi MeneghiniDallas$136K
- Oksana HamidiDallas$106K
- Lance SloanLufkin$1.7M
- Robert HoodBeaumont$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.